the model was significantly improved comparing to the current UISS system (0.72 for U-HGRC vs 0.65 for UISS, p[.008) with an accuracy of 82.8% for the U-HGRC high-risk group.
INTRODUCTION AND OBJECTIVES:
Despite strong safety and accuracy data, renal biopsy utilization remains low. Proponents of no-biopsy argue that "it would not change management" since biopsy cohorts used in existing studies may not be representative of those progressing to treatment.
In a multi-institutional nephrectomy (treatment) cohort, we performed a cost-effectiveness analysis of renal biopsy to alter management and save costs in patients who have (would have) undergone intervention.
METHODS: We completed a decision analysis (Figure 1 ) populated by a multi-institutional, multi-provincial Canadian cohort from 2013 to 2015. Outcomes and costing data were compared against reference literature values for generalizability to other jurisdictions.
We completed probabilistic (Monte Carlo simulation, normal distributions) and deterministic sensitivity analyses for all model inputs across min-max published literature values. Non-diagnostic biopsies were re-biopsied once. Given our low event rate and risk of bias, literature rates were used for false negative and false positive rates within the model. TreeAgePro software was used.
RESULTS: 542 patients were included: 192 (35%) received pre-operative biopsy and 58 (10.7%) had benign disease on nephrectomy pathology. 14 (7.3%) had discordant pathology between biopsy and nephrectomy; however, most of these would not have altered management (i.e. malignant disease misclassified between clear cell, papillary, chromophobe or oncocytic neoplasm NOS). 7 (3.6%) were non-diagnostic biopsies. Using final pathology as a gold standard and correcting for biopsy accuracy, we found a number needed to biopsy (NNTB) of 10.4 biopsies per nephrectomy avoided.
Results were most sensitive to parameter uncertainty around probability of benign disease, cost of surgery ($12,425) , and of biopsy ($1,137). After 50 000 simulations, biopsy was cost saving ($11,933 vs $12,416, threshold 6 .9% likelihood of pre-operative benign disease). In sub-analysis of non-biopsy centres only (16% benign disease), cost savings increased (biopsy $11,385) and NNTB fell to 7.0 biopsies per nephrectomy avoided.
CONCLUSIONS: Even prior to incorporating quality of life benefit from avoiding unnecessary operation and the cost of surgical complications, we demonstrate clinical and cost effectiveness of incorporating renal biopsy as a useful tool in pre-operative planning.
Source of Funding: None

MP14-05 EFFECT OF RENAL BIOPSIES ON THE MANAGEMENT OF RENAL MASSES IN A HIGH-VOLUME CENTER
Valeria Tringali*, Deliu Victor Matei, Giuseppe Renne, Paolo Della Vigna, Ottavio de Cobelli, Milano, Italy INTRODUCTION AND OBJECTIVES: The standard of care for renal masses and localized renal cancer is still debated. Both nephron sparing approaches (surgery (NSS) or percutaneous thermal ablation (PTA)) or radical nephrectomy (RN) bear the risks of postoperative complications, while in the case of benign lesions, they are useless or even harmful. On the contrary, active surveillance (AS) carries the risk of progression. Although percutaneous needle-renal biopsy (PNRB) seems appropriate to guide therapeutic decision, it is still far from being widely accepted and diffused.
METHODS: We retrospectively reviewed our pathology archives of operated and biopsied renal masses from 1999 to 2017 and considered those having had a benign pathology.
RESULTS: 1281 kidney surgery procedures were performed for radiologic suspicious malignant renal masses. Of these, 118 (9.2%) resulted in benign lesions at final pathology. 71 of them underwent NSsurgery, scilicet 15.8% of all NSS, while 47 underwent RN (5.7% of all RN). Our institution began to perform PNRB in 1999, with a steep increase in the number of procedures per year in the last decade, and a low rate of adverse effects. Biopsy result was inconclusive in 8 (6.8%) of the benign cases, requiring new biopsy. Benign versus malignant discordance between biopsy and surgery was seen in 4 cases. Therapy of benign lesions according to the biopsy status is reported in Tab. 1.
Time-evolution of overall therapeutic approaches is shown in Graph 1.
CONCLUSIONS: Renal biopsy allows an appropriate management of benign lesions by avoiding overtreatment. It has a favorable
